Edward Rapp - AbbVie Independent Director
| ABBV Stock | USD 171.73 3.97 2.37% |
Director
Mr. Edward J. Rapp is an Independent Director of the Company. Mr. Rapp served as the Caterpillar Inc. group president for resource industries from 2014 until his retirement in mid2016. He previously served at Caterpillar as group president based in Singapore in 2013 and 2014 and as the chief financial officer from 2010 to 2013, and he was named a group president in 2007 since 2013.
| Age | 63 |
| Tenure | 11 years |
| Address | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
Edward Rapp Latest Insider Activity
Tracking and analyzing the buying and selling activities of Edward Rapp against AbbVie stock is an integral part of due diligence when investing in AbbVie. Edward Rapp insider activity provides valuable insight into whether AbbVie is net buyers or sellers over its current business cycle. Note, AbbVie insiders must abide by specific rules, including filing SEC forms every time they buy or sell AbbVie'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Edward Rapp over six months ago Acquisition by Edward Rapp of 212 shares of AbbVie at 182.1 subject to Rule 16b-3 |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0772 % which means that it generated a profit of $0.0772 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5641 %, meaning that it created $0.5641 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AbbVie's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.65 in 2024, whereas Return On Tangible Assets are likely to drop 0.1 in 2024. At this time, AbbVie's Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 8.9 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 57.7 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dan Littman | Pfizer Inc | 68 | |
| Thomas Cech | Merck Company | 72 | |
| Anne Mulcahy | Johnson Johnson | 68 | |
| Susan Hockfield | Pfizer Inc | 70 | |
| Scott Gottlieb | Pfizer Inc | 48 | |
| Kathy Warden | Merck Company | 49 | |
| Mary Coe | Merck Company | 54 | |
| Shantanu Narayen | Pfizer Inc | 57 | |
| Marillyn Hewson | Johnson Johnson | 67 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| Phyllis Yale | Bristol Myers Squibb | 63 | |
| Mark McClellan | Johnson Johnson | 57 | |
| James Quincey | Pfizer Inc | 56 | |
| Leslie Brun | Merck Company | 68 | |
| Kathi Seifert | Eli Lilly and | 70 | |
| Marschall Runge | Eli Lilly and | 66 | |
| Darius Adamczyk | Johnson Johnson | 55 | |
| Ronald Blaylock | Pfizer Inc | 61 | |
| Carolyn Bertozzi | Eli Lilly and | 53 | |
| Michael Eskew | Eli Lilly and | 71 | |
| Theodore Samuels | Bristol Myers Squibb | 66 | |
Management Performance
| Return On Equity | 0.56 | ||||
| Return On Asset | 0.0772 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Azita Gerhardt, Executive Vice President - Operations | ||
| Carlos Alban, Vice Chairman, Chief Commercial Officer | ||
| Robert Michael, Vice Chairman, Finance and Commercial Operations and Chief Financial Officer | ||
| Jeffrey Stewart, Executive Vice President, Chief Commercial Officer | ||
| Carrie Strom, Senior Vice President AbbVie and President Global Allergan Aesthetics | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President - Finance and Administration | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, General VP | ||
| Azita SalekiGerhardt, Executive Vice President - Operations | ||
| Scott Reents, Executive CFO | ||
| Thomas Freyman, Independent Director | ||
| Thomas MD, Senior Research | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman, CEO and Chairman of Executive Committee | ||
| Tracie Haas, Brand Responsibility | ||
| Sanjay Narayan, Chief SVP | ||
| Brian Durkin, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Thomas Hudson, Senior Vice President Research & Development and Chief Scientific Officer | ||
| Roopal MD, Executive Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Assil Omar, VP Officer | ||
| Greg Miley, Senior Affairs | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, Senior Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Elaine Sorg, Senior Vice President U.S. Commercial Operations | ||
| WulffErik Borcke, Senior Oncology | ||
| Timothy Richmond, Chief Human Resource Officer, Executive Vice President | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive VP of Bus. Devel. and External Affairs, General Counsel and Corporate Secretary | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Independent Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.56 | ||||
| Return On Asset | 0.0772 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 367.27 B | ||||
| Shares Outstanding | 1.77 B | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 73.33 % | ||||
| Number Of Shares Shorted | 18.13 M | ||||
| Price To Earning | 21.28 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.